Skip to main content
SP5007,711.76-0.25%DOW53,559.99-0.02%NASDAQ26,402.42-0.52%BTC$77,728.00-3.40%ETH$2,441.16-2.91%GOLD$4,504.10-3.43%OIL$83.44-0.11%
Smart Investors Daily
Sign InSign Up Free
Kenvue Inc. logo

NYSE · KVUE

Kenvue Inc.

Consumer Defensive · Household & Personal Products

$19.17

Down-$0.03 (-0.16%)

Updated Aug 30, 2026, 5:52 AM

SID Score

6.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
33.2B
P/E ratio
23.19
Dividend yield
4.31%
52-week range
$16.56 – $20.13
Volume
11.89M
Avg. volume
40.52M

Price performance

KVUE price history

1M range · 20 trading sessions · Daily adjusted prices

KVUE closed at $19.17 after 20 trading sessions, up 0.84% for the selected period.

Last close
$19.17
Period change
+0.84%
Period low
$18.79
Period high
$19.67
Daily close
View OHLC price history
KVUE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 28, 2026$19.26$19.39$19.13$19.1711.89M
Aug 27, 2026$19.04$19.2499$18.985$19.2014.74M
Aug 26, 2026$19.42$19.47$19.21$19.2225.4M
Aug 25, 2026$19.28$19.38$19.175$19.3320.42M
Aug 24, 2026$19.10$19.56$19.10$19.4316.1M
Aug 21, 2026$18.97$19.16$18.87$19.0613.57M
Aug 20, 2026$19.04$19.16$18.87$18.9317.71M
Aug 19, 2026$18.91$19.185$18.88$19.1336.19M
Aug 18, 2026$19.00$19.1151$18.80$18.8025.52M
Aug 17, 2026$19.04$19.04$18.735$18.7927.97M
Aug 14, 2026$19.19$19.31$19.13$19.2010.36M
Aug 13, 2026$19.02$19.285$19.02$19.2017.04M
Aug 12, 2026$18.69$19.06$18.65$18.9811.03M
Aug 11, 2026$18.90$19.10$18.88$19.0512.78M
Aug 10, 2026$19.03$19.16$18.89$19.0325.55M
Aug 7, 2026$19.085$19.27$18.865$19.2314.33M
Aug 6, 2026$19.54$19.70$19.01$19.1825.33M
Aug 5, 2026$19.53$19.67$19.065$19.6732.81M
Aug 4, 2026$19.00$19.61$18.685$19.5523.6M
Aug 3, 2026$19.38$19.685$18.775$19.0135.17M

Latest KVUE news

The latest Smart Investors Daily articles mentioning KVUE.

Stock researchCompany · Overview

KVUE research

Overview

Company profile and research snapshot.

Company profile

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.57
Implied upside
—
Analysts
—
KVUE recent ratings
DateFirmRatingTarget
Aug 11, 2026UBSNeutral—
Jul 21, 2026BarclaysEqual-Weight—
Jul 16, 2026UBSNeutral—
Apr 15, 2026CitigroupNeutral—
Apr 14, 2026BarclaysEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 21, 2026

Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings

Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...

Yahoo · Aug 21, 2026

Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?

In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By